Clinical trials for CAR T- Cell therapy for treatment of some types of blood cancer trials have kicked off at the Advanced Centre for Treatment, Research and Education in Cancer the research and development wing of Tata Memorial Centre. “More details of the trial will be revealed soon,” Dr. Narula said in a press brief. This clinical trial is taking place with the help of researcher from IIT, Bombay who has developed this life saving therapy.
Dr Reddys lab has also secured a deal with Shenzen Biopharma Pregene of China in the month of May, 21 to bring this life saving therapy to India. There are several other companies that are also working to bring this technology to India. US-based Indian born oncologist Dr. Siddharth Mukherjee was in India recently and had a meeting with Kiran Mazumdar Shaw of Biocon & Mr. Kush Parmar of 5 AM ventures.
All of them have agreed to come up with a facility to grow a Chimeric Antigen Receptor (CAR) cells to fight cancer. As per the reports, this therapy can be available in India in about a year’s time. This therapy has recently been approved by FDA (Food and drug administration). This cell therapy is useful for treatment in certain children and young adults suffering from Non – Hodgkin lymphoma. Treatment with Yeskarta & Kymriah is the first CAR T-Cell therapy to receive FDA approval.
Despite the fact that there are multiple cell therapy clinical trials active and enrolling in the United States, the European Union, and China, none have been available in India.
The new Immuneel facility in Bengaluru’s Narayana Health City is dedicated to introducing high-quality and affordable cell therapies to India. The facility’s strategic location in a tertiary care hospital near a high-volume bone marrow transplant unit allows for further coordination between research teams and clinicians, which is important for focused clinical development of innovative personalized therapies like CAR-T.
Sign in to leave a comment.